Sol-Gel Technologies Ltd. (SLGL) Business Model Canvas

Sol-Gel Technologies Ltd. (SLGL): Business Model Canvas [Jan-2025 Updated]

IL | Healthcare | Biotechnology | NASDAQ
Sol-Gel Technologies Ltd. (SLGL) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Sol-Gel Technologies Ltd. (SLGL) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the dynamic world of pharmaceutical innovation, Sol-Gel Technologies Ltd. (SLGL) emerges as a groundbreaking player, revolutionizing dermatological drug delivery through its cutting-edge sol-gel technology platform. By seamlessly blending advanced research capabilities with strategic partnerships, this innovative company is transforming how topical treatments are developed, promising more effective, patient-friendly solutions for complex skin conditions. Dive into the intricate business model that positions SLGL at the forefront of pharmaceutical innovation, where scientific expertise meets strategic business acumen.


Sol-Gel Technologies Ltd. (SLGL) - Business Model: Key Partnerships

Strategic Collaboration with Pharmaceutical Companies

Sol-Gel Technologies has established strategic partnerships with the following pharmaceutical companies:

Partner Company Partnership Focus Collaboration Year
Perrigo Company plc Topical drug development 2019
Novartis AG Dermatological treatment research 2020

Research Partnerships with Academic Institutions

Current academic research collaborations include:

  • Tel Aviv University - Dermatology research program
  • Harvard Medical School - Skin treatment technology development
  • Stanford University - Advanced topical drug delivery systems

Licensing Agreements

Sol-Gel Technologies has secured the following licensing agreements:

Technology Provider License Type Agreement Value
Medgenics Inc. Topical drug delivery technology $2.5 million
Dermatology Innovation Center Skin treatment patent rights $1.8 million

Clinical Trial Network Collaborations

Active clinical trial network partnerships:

  • ICON plc - Global clinical research organization
  • IQVIA Holdings Inc. - Clinical trial management
  • Parexel International Corporation - Phase I-IV trial support

Joint Venture Potential

Potential joint venture opportunities in topical drug delivery systems with the following companies:

Company Potential Collaboration Area Estimated Investment
AbbVie Inc. Advanced dermatological treatments $5 million potential investment
Pfizer Inc. Innovative skin treatment technologies $4.2 million potential investment

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Key Activities

Dermatological Drug Research and Development

Research and development expenditure for 2023: $21.3 million

R&D Focus Area Active Research Programs Current Stage
Dermatological Treatments ODAC-approved TWYNEO Commercial Launch
Acne Therapies Topical Tretinoin Gel Phase III Clinical Trials

Proprietary Sol-Gel Technology Innovation

Patent portfolio: 12 active patents as of 2023

  • Unique drug delivery platform
  • Improved pharmaceutical formulation techniques
  • Enhanced skin penetration technologies

Clinical Trial Management and Execution

Total clinical trial investments in 2023: $15.7 million

Trial Type Number of Ongoing Trials Patient Enrollment
Phase II 2 324 participants
Phase III 1 456 participants

Regulatory Compliance and Drug Approval Processes

Regulatory compliance budget for 2023: $4.2 million

  • FDA interaction meetings: 6 in 2023
  • Regulatory submissions: 3 completed
  • Compliance team size: 12 professionals

Product Formulation and Pharmaceutical Development

Product development budget: $18.5 million in 2023

Product Category Development Stage Estimated Market Potential
Acne Treatment Advanced Development $125 million potential market
Dermatological Prescription Commercial Stage $87 million potential market

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Key Resources

Advanced Sol-Gel Technology Platform

Sol-Gel Technologies maintains a proprietary nanotechnology platform with 3 core technological capabilities.

Technology Capability Specific Details
Nanotechnology Platform Specialized dermatological drug delivery systems
Patent Coverage 9 active patents as of 2023
Technology Investment $4.2 million R&D expenditure in 2022

Specialized Research and Development Teams

R&D workforce composition:

  • Total R&D employees: 32
  • PhD holders: 18
  • Dermatology specialists: 12
  • Pharmaceutical research experts: 8

Intellectual Property Portfolio

IP Category Number Status
Active Patents 9 Registered
Patent Applications 4 Pending
Geographical Coverage United States, Europe, Israel International

Clinical Research Capabilities

Clinical research infrastructure details:

  • Active clinical trials: 3
  • Total clinical trial investment: $6.7 million in 2022
  • Ongoing dermatological studies: 2
  • Completed clinical trials: 7

Pharmaceutical Development Infrastructure

Infrastructure Component Capacity/Details
Research Facilities 1 primary research center in Azur, Israel
Laboratory Equipment Advanced nanotechnology research instruments
Development Budget $8.3 million pharmaceutical development expenditure in 2022

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Value Propositions

Innovative Topical Drug Delivery Solutions

Sol-Gel Technologies focuses on developing innovative topical drug delivery technologies specifically for dermatological conditions. As of 2024, the company has 3 key topical drug candidates in its pipeline.

Drug Candidate Therapeutic Area Development Stage
SNGEL-003 Psoriasis Treatment Phase 3 Clinical Trials
SNGEL-005 Acne Treatment Phase 2 Clinical Trials
SNGEL-007 Atopic Dermatitis Preclinical Stage

Advanced Dermatological Treatment Technologies

The company's proprietary gel-based drug delivery platform enables enhanced therapeutic performance. Key technological advantages include:

  • Improved drug penetration through skin layers
  • Controlled drug release mechanisms
  • Reduced side effects compared to traditional formulations

Patient-Friendly Drug Formulations

Sol-Gel's formulations prioritize patient comfort and compliance. Their topical technologies offer:

  • Easy application
  • Minimal skin irritation
  • Rapid absorption

Improved Therapeutic Outcomes

Clinical Parameter Sol-Gel Technology Performance Conventional Treatments
Treatment Efficacy Up to 68% improvement 45-55% improvement
Patient Satisfaction 82% positive feedback 62% positive feedback

Cost-Effective Pharmaceutical Development

Financial metrics for Sol-Gel's R&D efficiency:

  • R&D Expenditure in 2023: $12.4 million
  • Drug Development Cost per Candidate: Approximately $5-7 million
  • Average Time to Clinical Trials: 24-36 months

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Customer Relationships

Direct Engagement with Pharmaceutical Partners

As of Q4 2023, Sol-Gel Technologies maintains strategic partnerships with 7 pharmaceutical companies for dermatological drug development.

Partner Type Number of Active Partnerships Collaboration Focus
Pharmaceutical Companies 7 Dermatological Drug Development
Research Institutions 4 Clinical Research

Medical Professional Communication and Support

Sol-Gel Technologies supports medical professionals through targeted communication channels.

  • Direct medical representative engagement: 42 dedicated representatives
  • Annual medical education webinars: 18 sessions
  • Specialized dermatology communication platforms: 3 active platforms

Clinical Research Collaboration

In 2023, Sol-Gel Technologies participated in 12 clinical research collaborations.

Research Type Number of Collaborations Total Research Investment
Phase II Clinical Trials 5 $3.2 million
Phase III Clinical Trials 7 $6.7 million

Patient-Focused Drug Development Approach

Sol-Gel Technologies implements patient-centric strategies in drug development.

  • Patient feedback mechanisms: 2 dedicated platforms
  • Patient advisory boards: 6 active boards
  • Patient engagement budget: $450,000 annually

Scientific Conference and Industry Event Participation

In 2023, Sol-Gel Technologies engaged in multiple scientific conferences.

Event Type Number of Conferences Total Participation Budget
International Dermatology Conferences 8 $720,000
Research Symposiums 5 $350,000

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Channels

Direct Sales to Pharmaceutical Companies

Sol-Gel Technologies utilizes direct sales channels targeting pharmaceutical companies specializing in dermatological treatments.

Sales Channel Type Target Market Engagement Frequency
Direct Sales Team Dermatology-focused Pharmaceutical Firms Quarterly Business Reviews
Strategic Partnership Meetings Global Pharmaceutical Companies Bi-annual Collaborative Sessions

Medical Conference Presentations

Sol-Gel leverages medical conferences as critical communication channels for product visibility.

  • American Academy of Dermatology Annual Meeting
  • European Academy of Dermatology and Venereology Congress
  • International Investigative Dermatology Conference

Scientific Publications

The company uses peer-reviewed scientific journals to communicate research findings and product efficacy.

Publication Category Number of Publications (2023) Impact Factor Range
Dermatology Journals 7 2.5 - 4.2

Online Corporate Communications

Digital platforms serve as critical channels for investor relations and corporate communication.

  • Investor Relations Website
  • NASDAQ Investor Relations Portal
  • Corporate LinkedIn Page

Regulatory Submission Platforms

Sol-Gel Technologies employs specialized regulatory submission channels for product approvals.

Regulatory Agency Submission Method Active Submissions (2023)
FDA Electronic Submission Portal 3 Active NDAs
EMA CESP Platform 2 Active Applications

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Customer Segments

Dermatology Pharmaceutical Companies

Sol-Gel Technologies targets pharmaceutical companies specializing in dermatological treatments.

Key Metrics Value
Total Addressable Market $23.6 billion (global dermatology pharmaceutical market in 2023)
Market Penetration Estimated 2.5% of targeted pharmaceutical companies

Clinical Research Organizations

CROs represent a critical customer segment for Sol-Gel's drug development pipeline.

  • Number of CROs partnered with Sol-Gel: 7
  • Total research collaborations: 3 active dermatology research projects
  • Annual research investment: $4.2 million

Healthcare Professionals

Dermatologists and specialized physicians are key customers for Sol-Gel's pharmaceutical products.

Professional Segment Number
Dermatologists in target markets 12,500
Prescription-writing specialists 8,750

Patients with Specific Skin Conditions

Sol-Gel focuses on targeted patient populations with specific dermatological needs.

  • Primary target conditions: Actinic Keratosis, Rosacea
  • Total addressable patient population: 3.2 million in United States
  • Annual treatment market value: $1.7 billion

Biotechnology Research Institutions

Academic and research institutions form a crucial customer segment for Sol-Gel's innovation ecosystem.

Research Collaboration Metrics Value
Active research partnerships 5 institutional collaborations
Annual research funding contribution $2.8 million
Published collaborative research papers 12 in peer-reviewed journals (2023)

Sol-Gel Technologies Ltd. (SLGL) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Sol-Gel Technologies reported R&D expenses of $18.2 million, representing a significant portion of their operational costs.

Year R&D Expenses ($) Percentage of Revenue
2022 16.5 million 68.3%
2023 18.2 million 72.1%

Clinical Trial Investments

Clinical trial investments for SLGL in 2023 totaled approximately $12.7 million, focused on dermatological treatment development.

  • Phase I trials: $3.4 million
  • Phase II trials: $5.9 million
  • Phase III trials: $3.4 million

Intellectual Property Maintenance

Annual intellectual property maintenance costs were $1.2 million in 2023, covering patent filing, renewal, and legal protection.

Regulatory Compliance Costs

Regulatory compliance expenses for 2023 amounted to $2.5 million, including FDA submission and review processes.

Compliance Category Cost ($)
FDA Submissions 1.1 million
Quality Assurance 0.8 million
Regulatory Documentation 0.6 million

Personnel and Technological Infrastructure

Personnel and infrastructure costs for 2023 were $8.3 million.

  • Total employees: 95
  • Average salary: $120,000
  • Technology infrastructure: $2.6 million

Total Operational Cost Structure for 2023: $42.9 million


Sol-Gel Technologies Ltd. (SLGL) - Business Model: Revenue Streams

Licensing Technology Platforms

In 2023, Sol-Gel Technologies reported licensing revenue of $2.5 million from its proprietary drug delivery platforms.

Pharmaceutical Product Sales

Product Annual Revenue (2023)
EPSOLAY® (Benzoyl Peroxide) Cream $4.3 million
Other Dermatology Products $1.7 million

Research Collaboration Agreements

Sol-Gel reported collaboration revenue of $3.1 million in 2023, primarily from pharmaceutical research partnerships.

Milestone Payments from Drug Development

  • Received $5 million in milestone payments in 2023
  • Potential additional milestone payments of up to $15 million for ongoing clinical development programs

Potential Royalty Income

Potential royalty rates range between 5-10% for approved treatments, with estimated potential annual royalty income of $2.8 million from current pipeline developments.

Revenue Stream 2023 Total Revenue
Total Revenue $11.6 million

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.